Erratum: NT5E mutations that cause human disease are associated with intracellular mistrafficking of NT5E protein (PLoS ONE (2014) 9:6 (e98568) doi: 10.1371/journal.pone.0098568);NT5E mutations that cause human disease are associated with intracellular mistrafficking of NT5E protein

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Fausther, Michel ^a,b   Lavoie, Elise G ^a,b   Goree, Jessica R ^a,b   Baldini, Giulia ^a   Dranoff, Jonathan A ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b VA Central Arkansas Healthcare System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE KINASE; COMPLEMENTARY DNA; ECTO 5' NUCLEOTIDASE; 5' NUCLEOTIDASE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; NT5E PROTEIN, HUMAN;

ANIMAL CELL; ARTERY CALCIFICATION; ARTICLE; CATALYSIS; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME ACTIVITY; EXPRESSION VECTOR; GENE MUTATION; GENETIC ASSOCIATION; HOMOZYGOSITY; NONHUMAN; NT5E GENE; NUCLEOTIDE SEQUENCE; PLASMID; PROTEIN CLEAVAGE; PROTEIN TRANSPORT; WESTERN BLOTTING; ANIMAL; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; GENETICS; HUMAN; MUTATION;

5'-NUCLEOTIDASE; ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; GPI-LINKED PROTEINS; HUMANS; MUTATION;

EID: 84902313069     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0118252     Document Type: Erratum

References (51)

1. Zimmermann H, Zebisch M, Strater N (2012) Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal 8: 437-502.
2. Colgan SP, Eltzschig HK, Eckle T, Thompson LF (2006) Physiological roles for ecto-5′-nucleotidase (CD73). Purinergic Signal 2: 351-360.
3. Airas L (1998) CD73 and adhesion of B-cells to follicular dendritic cells. Leuk Lymphoma 29: 37-47.
4. Koso H, Minami C, Tabata Y, Inoue M, Sasaki E, et al. (2009) CD73, a novel cell surface antigen that characterizes retinal photoreceptor precursor cells. Invest Ophthalmol Vis Sci 50: 5411-5418.
5. Barry F, Boynton R, Murphy M, Haynesworth S, Zaia J (2001) The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells. Biochem Biophys Res Commun 289: 519-524. (Pubitemid 33141085)
6. Pfister S, Dietrich MG, Sidler C, Fritschy JM, Knuesel I, et al. (2012) Characterization and turnover of CD73/IP(3)R3-positive microvillar cells in the adult mouse olfactory epithelium. Chem Senses 37: 859-868.
7. Fausther M, Lavoie EG, Dranoff JA (2013) Contribution of Myofibroblasts of Different Origins to Liver Fibrosis. Curr Pathobiol Rep 1: 225-230.
8. Antonioli L, Pacher P, Vizi ES, Hasko G (2013) CD39 and CD73 in immunity and inflammation. Trends Mol Med 19: 355-367.
9. Martin-Satue M, Lavoie EG, Fausther M, Lecka J, Aliagas E, et al. (2010) High expression and activity of ecto-5′-nucleotidase/CD73 in the male murine reproductive tract. Histochem Cell Biol 133: 659-668.
10. Ernst PB, Garrison JC, Thompson LF (2010) Much ado about adenosine: adenosine synthesis and function in regulatory T cell biology. J Immunol 185: 1993-1998.
11. Airas L, Niemela J, Jalkanen S (2000) CD73 engagement promotes lymphocyte binding to endothelial cells via a lymphocyte function-associated antigen-1-dependent mechanism. J Immunol 165: 5411-5417.
12. Airas L, Jalkanen S (1996) CD73 mediates adhesion of B cells to follicular dendritic cells. Blood 88: 1755-1764. (Pubitemid 26307072)
13. Sadej R, Skladanowski AC (2012) Dual, enzymatic and non-enzymatic, function of ecto-5′-nucleotidase (eN, CD73) in migration and invasion of A375 melanoma cells. Acta Biochim Pol 59: 647-652.
14. St Hilaire C, Ziegler SG, Markello TC, Brusco A, Groden C, et al. (2011) NT5E mutations and arterial calcifications. N Engl J Med 364: 432-442.
15. Klemens MR, Sherman WR, Holmberg NJ, Ruedi JM, Low MG, et al. (1990) Characterization of soluble vs membrane-bound human placental 5′-nucleotidase. Biochem Biophys Res Commun 172: 1371-1377.
16. Sowa NA, Voss MK, Zylka MJ (2010) Recombinant ecto-5′-nucleotidase (CD73) has long lasting antinociceptive effects that are dependent on adenosine A1 receptor activation. Mol Pain 6: 20.
17. Misumi Y, Ogata S, Ohkubo K, Hirose S, Ikehara Y (1990) Primary structure of human placental 5′-nucleotidase and identification of the glycolipid anchor in the mature form. Eur J Biochem 191: 563-569.
18. Tkacz K, Cioroch M, Skladanowski AC, Makarewicz W (2000) The cytotoxic effect of purine riboside on COS-7 cells. Adv Exp Med Biol 486: 355-359. (Pubitemid 32179325)
19. Cheng SH, Fang SL, Zabner J, Marshall J, Piraino S, et al. (1995) Functional activation of the cystic fibrosis trafficking mutant delta F508-CFTR by overexpression. Am J Physiol 268: L615-624.
20. Rubenstein RC, Egan ME, Zeitlin PL (1997) In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest 100: 2457-2465. (Pubitemid 27514885)
21. Murakami Y, Kanzawa N, Saito K, Krawitz PM, Mundlos S, et al. (2012) Mechanism for release of alkaline phosphatase caused by glycosylphosphatidylinositol deficiency in patients with hyperphosphatasia mental retardation syndrome. J Biol Chem 287: 6318-6325.
22. Ito M, Amizuka N, Ozawa H, Oda K (2002) Retention at the cis-Golgi and delayed degradation of tissue-non-specific alkaline phosphatase with an Asn153 - >Asp substitution, a cause of perinatal hypophosphatasia. Biochem J 361: 473-480. (Pubitemid 34177816)
23. Shibata H, Fukushi M, Igarashi A, Misumi Y, Ikehara Y, et al. (1998) Defective intracellular transport of tissue-nonspecific alkaline phosphatase with an Ala162 - >Thr mutation associated with lethal hypophosphatasia. J Biochem 123: 968-977. (Pubitemid 28226997)
24. Rogan MP, Stoltz DA, Hornick DB (2011) Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment. Chest 139: 1480-1490.
25. Catoire H, Pasco MY, Abu-Baker A, Holbert S, Tourette C, et al. (2008) Sirtuin inhibition protects from the polyalanine muscular dystrophy protein PABPN1. Hum Mol Genet 17: 2108-2117. (Pubitemid 351911980)
26. Zimmermann H (1992) 5′-Nucleotidase: molecular structure and functional aspects. Biochem J 285 (Pt 2): 345-365.
27. Hausler SF, Del Barrio IM, Diessner J, Stein RG, Strohschein J, et al. (2014) Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion. Am J Transl Res 6: 129-139.
28. Antonioli L, Blandizzi C, Pacher P, Hasko G (2013) Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 13: 842-857.
29. Resta R, Yamashita Y, Thompson LF (1998) Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol Rev 161: 95-109.
30. Sadej R, Inai K, Rajfur Z, Ostapkowicz A, Kohler J, et al. (2008) Tenascin C interacts with ecto-5′-nucleotidase (eN) and regulates adenosine generation in cancer cells. Biochim Biophys Acta 1782: 35-40.
31. Wang L, Zhou X, Zhou T, Ma D, Chen S, et al. (2008) Ecto-5′- nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin Oncol 134: 365-372. (Pubitemid 351170058)
32. Stagg J, Beavis PA, Divisekera U, Liu MC, Moller A, et al. (2012) CD73-deficient mice are resistant to carcinogenesis. Cancer Res 72: 2190-2196.
33. Stagg J, Divisekera U, Duret H, Sparwasser T, Teng MW, et al. (2011) CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res 71: 2892-2900.
34. Terp MG, Olesen KA, Arnspang EC, Lund RR, Lagerholm BC, et al. (2013) Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells. J Immunol 191: 4165-4173.
35. Fukushi-Irie M, Ito M, Amaya Y, Amizuka N, Ozawa H, et al. (2000) Possible interference between tissue-non-specific alkaline phosphatase with an Arg54 - >Cys substitution and acounterpart with an Asp277 - >Ala substitution found in a compound heterozygote associated with severe hypophosphatasia. Biochem J 348 Pt 3: 633-642. (Pubitemid 30410254)
36. Fernandez P, Perez-Aso M, Smith G, Wilder T, Trzaska S, et al. (2013) Extracellular generation of adenosine by the ectonucleotidases CD39 and CD73 promotes dermal fibrosis. Am J Pathol 183: 1740-1746.
37. Peng Z, Fernandez P, Wilder T, Yee H, Chiriboga L, et al. (2008) Ecto-5′-nucleotidase (CD73)-mediated extracellular adenosine production plays a critical role in hepatic fibrosis. FASEB J 22: 2263-2272. (Pubitemid 351948645)
38. Volmer JB, Thompson LF, Blackburn MR (2006) Ecto-5′-nucleotidase (CD73)-mediated adenosine production is tissue protective in a model of bleomycin-induced lung injury. J Immunol 176: 4449-4458. (Pubitemid 44264425)
39. Bonner F, Borg N, Jacoby C, Temme S, Ding Z, et al. (2013) Ecto-5′-nucleotidase on immune cells protects from adverse cardiac remodeling. Circ Res 113: 301-312.
40. Snider NT, Griggs NW, Singla A, Moons DS, Weerasinghe SV, et al. (2013) CD73 (ecto-5′-nucleotidase) hepatocyte levels differ across mouse strains and contribute to mallory-denk body formation. Hepatology 58: 1790-1800.
41. Hasko G, Csoka B, Koscso B, Chandra R, Pacher P, et al. (2011) Ecto-5′-nucleotidase (CD73) decreases mortality and organ injury in sepsis. J Immunol 187: 4256-4267.
42. Alam MS, Kuo JL, Ernst PB, Derr-Castillo V, Pereira M, et al. (2014) Ecto-5′-nucleotidase (CD73) regulates host inflammatory responses and exacerbates murine salmonellosis. Sci Rep 4: 4486.
43. Petrikovics I, Wales M, Budai M, Yu JC, Szilasi M (2012) Nano-intercalated organophosphorus-hydrolyzing enzymes in organophosphorus antagonism. AAPS PharmSciTech 13: 112-117.
44. Rowe SM, Clancy JP (2009) Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development. BioDrugs 23: 165-174.
45. Gahl WA, Boerkoel CF, Boehm M (2012) The NIH Undiagnosed Diseases Program: bonding scientists and clinicians. Dis Model Mech 5: 3-5.
46. Fausther M, Lecka J, Soliman E, Kauffenstein G, Pelletier J, et al. (2012) Coexpression of ecto-5′-nucleotidase/CD73 with specific NTPDases differentially regulates adenosine formation in the rat liver. Am J Physiol Gastrointest Liver Physiol 302: G447-459.
47. Kukulski F, Levesque SA, Lavoie EG, Lecka J, Bigonnesse F, et al. (2005) Comparative hydrolysis of P2 receptor agonists by NTPDases 1, 2, 3 and 8. Purinergic Signal 1: 193-204. (Pubitemid 40475234)
48. Baykov AA, Evtushenko OA, Avaeva SM (1988) A malachite green procedure for orthophosphate determination and its use in alkaline phosphatase-based enzyme immunoassay. Anal Biochem 171: 266-270.
49. Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, et al. (2005) Protein Identification and Analysis Tools on the ExPASy Server. In: Walker JM, editor. The Proteomics Protocols Handbook: Humana Press.pp. 571-607.
50. Petersen TN, Brunak S, von Heijne G, Nielsen H (2011) SignalP 4.0: discriminating signal peptides from transmembrane regions. Nat Methods 8: 785-786.
51. Fankhauser N, Maser P (2005) Identification of GPI anchor attachment signals by a Kohonen self-organizing map. Bioinformatics 21: 1846-1852. (Pubitemid 40668020)